Anti-β2GPI/β2GPI complexes induce platelet activation and promote thrombosis via p38MAPK: a pathway to targeted therapies

doi:10.1007/s11684-018-0673-5

Frontiers of Medicine

2019, Vol. 13

Issue (6): 680-689 https://doi.org/10.1007/s11684-018-0673-5

本期目录

Anti-β₂GPI/β₂GPI complexes induce platelet activation and promote thrombosis via p38MAPK: a pathway to targeted therapies

Wenjing Zhang¹, Caijun Zha¹, Xiumin Lu¹, Ruichun Jia¹, Fei Gao¹, Qi Sun², Meili Jin¹, Yanhong Liu¹(

)

¹. Department of Laboratory Diagnosis, The Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China
². Department of Emergency, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin 150040, China

全文: PDF(3836 KB) HTML

Abstract：

Anti-β₂ glycoprotein I (anti-β₂GPI) antibodies are important contributors to the development of thrombosis. Anti-β₂GPI antibody complexes with β₂GPI are well known to activate monocytes and endothelial cells via the intracellular NF-kB pathway with prothrombotic implications. By contrast, the interaction of anti-β₂GPI/β₂GPI complexes with platelets has not been extensively studied. The p38 mitogen-activated protein kinase (MAPK) pathway has been recognized to be an important intracellular signaling pathway in the coagulation cascade and an integral component of arterial and venous thrombosis. The present study reveals that levels of anti-β₂GPI/β₂GPI complexes in sera are positively associated with p38MAPK phosphorylation of platelets in thrombotic patients. Furthermore, SB203580 inhibits anti-β₂GPI/β₂GPI complex-induced platelet activation. Thrombus formation decreased in p38MAPK⁻^/⁻ mice after treatment with anti-β₂GPI/β₂GPI complexes. In conclusion, p38MAPK may be a treatment target for anti-β₂GPI antibody-associated thrombotic events.

Key words： anti-β₂GPI antibody β₂GPI platelet p38MAPK thrombosis complex

收稿日期: 2018-04-08 出版日期: 2019-12-16

Corresponding Author(s): Yanhong Liu

引用本文:

. [J]. Frontiers of Medicine, 2019, 13(6): 680-689.
Wenjing Zhang, Caijun Zha, Xiumin Lu, Ruichun Jia, Fei Gao, Qi Sun, Meili Jin, Yanhong Liu. Anti-β₂GPI/β₂GPI complexes induce platelet activation and promote thrombosis via p38MAPK: a pathway to targeted therapies. Front. Med., 2019, 13(6): 680-689.

链接本文:

https://academic.hep.com.cn/fmd/CN/10.1007/s11684-018-0673-5
https://academic.hep.com.cn/fmd/CN/Y2019/V13/I6/680

Tab.1

Fig.1

Fig.2

Fig.3

Fig.4

Fig.5

Fig.6

1	MM Bala, EM Paszek, D Wloch-Kopec, W Lesniak, A Undas. Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies. The Cochrane Library. John Wiley & Sons, Ltd., 2017
2	R Forastiero. Antiphospholipid syndrome: new light comes from in vivo studies. J Thromb Haemost 2007; 5(9): 1825–1827 https://doi.org/10.1111/j.1538-7836.2007.02686.x pmid: 17723120
3	C Zha, W Zhang, F Gao, J Xu, R Jia, J Cai, Y Liu. Anti-b2GPI/b2GPI induces neutrophil extracellular traps formation to promote thrombogenesis via the TLR4/MyD88/MAPKs axis activation. Neuropharmacology 2018; 138: 140–150 https://doi.org/10.1016/j.neuropharm.2018.06.001 pmid: 29883691
4	Y Zhang, W Zhang, C Zha, Y Liu. Platelets activated by the anti-b2GPI/b2GPI complex release microRNAs to inhibit migration and tube formation of human umbilical vein endothelial cells. Cell Mol Biol Lett 2018; 23(1): 24 https://doi.org/10.1186/s11658-018-0091-3 pmid: 29785186
5	E Raschi, CB Chighizola, C Grossi, N Ronda, R Gatti, PL Meroni, MO Borghi. b2-glycoprotein I, lipopolysaccharide and endothelial TLR4: three players in the two hit theory for anti-phospholipid-mediated thrombosis. J Autoimmun 2014; 55: 42–50 https://doi.org/10.1016/j.jaut.2014.03.001 pmid: 24685231
6	J Zhang, KR McCrae. Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-b2 glycoprotein I antibodies. Blood 2005; 105(5): 1964–1969 https://doi.org/10.1182/blood-2004-05-1708 pmid: 15471954
7	T Shi, B Giannakopoulos, X Yan, P Yu, MC Berndt, RK Andrews, J Rivera, GM Iverson, KA Cockerill, MD Linnik, SA Krilis. Anti-b2-glycoprotein I antibodies in complex with b2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum 2006; 54(8): 2558–2567 https://doi.org/10.1002/art.21968 pmid: 16868978
8	R Seger, EG Krebs. The MAPK signaling cascade. FASEB J 1995; 9(9): 726–735 https://doi.org/10.1096/fasebj.9.9.7601337 pmid: 7601337
9	R Bassi, R Heads, MS Marber, JE Clark. Targeting p38-MAPK in the ischaemic heart: kill or cure? Curr Opin Pharmacol 2008; 8(2): 141–146 https://doi.org/10.1016/j.coph.2008.01.002 pmid: 18289939
10	I Canobbio, S Reineri, F Sinigaglia, C Balduini, M Torti. A role for p38 MAP kinase in platelet activation by von Willebrand factor. Thromb Haemost 2004; 91(1): 102–110 https://doi.org/10.1160/TH03-02-0083 pmid: 14691575
11	H Cakmak, Y Seval-Celik, S Arlier, O Guzeloglu-Kayisli, F Schatz, A Arici, UA Kayisli. p38 mitogen-activated protein kinase is involved in the pathogenesis of endometriosis by modulating inflammation, but not cell survival. Reprod Sci 2018; 25(4): 587–597 https://doi.org/10.1177/1933719117725828 pmid: 28845752
12	W Zhang, F Gao, D Lu, N Sun, X Yin, M Jin, Y Liu. Anti-b2 glycoprotein I antibodies in complex with b2 glycoprotein I induce platelet activation via two receptors: apolipoprotein E receptor 2′ and glycoprotein I ba. Front Med 2016; 10(1): 76–84 https://doi.org/10.1007/s11684-015-0426-7 pmid: 26620053
13	A Biasiolo, P Rampazzo, T Brocco, F Barbero, A Rosato, V Pengo. [Anti-b2 glycoprotein I-b2 glycoprotein I] immune complexes in patients with antiphospholipid syndrome and other autoimmune diseases. Lupus 1999; 8(2): 121–126 https://doi.org/10.1191/096120399678847506 pmid: 10192506
14	G Andonegui, SM Kerfoot, K McNagny, KV Ebbert, KD Patel, P Kubes. Platelets express functional Toll-like receptor-4. Blood 2005; 106(7): 2417–2423 https://doi.org/10.1182/blood-2005-03-0916 pmid: 15961512
15	F Fischetti, P Durigutto, V Pellis, A Debeus, P Macor, R Bulla, F Bossi, F Ziller, D Sblattero, P Meroni, F Tedesco. Thrombus formation induced by antibodies to β2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005; 106(7): 2340–2346 https://doi.org/10.1182/blood-2005-03-1319 pmid: 15956288
16	PR Ames, J Delgado Alves, LR Lopez, F Gentile, A Margarita, L Pizzella, J Batuca, G Scenna, V Brancaccio, E Matsuura. Antibodies against β2-glycoprotein I complexed with an oxidised lipoprotein relate to intima thickening of carotid arteries in primary antiphospholipid syndrome. Clin Dev Immunol 2006; 13(1): 1–9 https://doi.org/10.1080/17402520600554930 pmid: 16603439

Viewed

Full text

Abstract

Cited

Shared

Discussed